Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $193,390.74 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 11,742 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $16.47, for a total transaction of $193,390.74. Following the completion of the sale, the insider now directly owns 159,782 shares of the company’s stock, valued at $2,631,609.54. This represents a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Centessa Pharmaceuticals Trading Down 0.3 %

Centessa Pharmaceuticals stock opened at $16.91 on Friday. Centessa Pharmaceuticals plc has a 52 week low of $7.38 and a 52 week high of $18.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm has a market capitalization of $2.23 billion, a PE ratio of -11.05 and a beta of 1.53. The business’s 50-day simple moving average is $16.77 and its 200-day simple moving average is $15.04.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. Equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC increased its holdings in shares of Centessa Pharmaceuticals by 27.6% during the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock worth $35,518,000 after purchasing an additional 850,000 shares during the period. FMR LLC increased its stake in Centessa Pharmaceuticals by 4.6% during the third quarter. FMR LLC now owns 2,916,494 shares of the company’s stock valued at $46,635,000 after acquiring an additional 129,300 shares during the period. Point72 Asset Management L.P. raised its holdings in Centessa Pharmaceuticals by 54.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after acquiring an additional 953,659 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after acquiring an additional 1,145,823 shares during the period. Finally, Janus Henderson Group PLC bought a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter worth approximately $20,698,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim increased their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.